José Luis
Pérez Gracia
Consultor Médico
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (20)
2024
2023
-
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
Clinical Cancer Research, Vol. 29, Núm. 17, pp. 3292-3300
2021
-
A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment
Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 434-449
-
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891
-
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology
ESMO Open
2020
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
-
Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients
Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348
2019
-
Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study
Medical Oncology, Vol. 36, Núm. 3
-
Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (47-56), 10.1007/s12094-017-1765-4)
Clinical and Translational Oncology
-
Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023))
European Urology
-
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial
Annals of Oncology, Vol. 30, Núm. 2, pp. 281-289
2018
-
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
European Urology, Vol. 73, Núm. 3, pp. 462-468
-
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer
Clinical Genitourinary Cancer, Vol. 16, Núm. 6, pp. e1133-e1139
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
-
SEOM clinical guideline for treatment of kidney cancer (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 47-56
2017
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial
The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550
2014
2006
-
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer
International Journal of Gynecological Cancer, Vol. 16, Núm. 1, pp. 71-76